Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

102.50 +2.16 (+2.15%)
Official Closing Price Updated: 4:15 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Gilead Sciences

< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
Opinion: Why Corporate Philanthropy Must Stand Against Stigma
SOURCE: Gilead Sciences 
Via 3BL Media
Diabetic Kidney Disease Market to Witness Upsurge in Growth During the Forecast Period – DelveInsight | Key Players – Bayer, Reata Pharma, Novartis, Dimerix, Kyowa Kirin, Gilead, Orbsen, and Others
Continue reading "Diabetic Kidney Disease Market to Witness Upsurge in Growth During the Forecast Period – DelveInsight | Key Players – Bayer, Reata Pharma, Novartis, Dimerix, Kyowa Kirin, Gilead,... 
Via Get News
Crohn’s Disease Market is Predicted to Exhibit Remarkable Growth by 2032, Analyzes DelveInsight | Key Companies – UCB, Abbvie, Genetech, Gilead, Celgene, Millennium Pharma, and Others
Continue reading "Crohn’s Disease Market is Predicted to Exhibit Remarkable Growth by 2032, Analyzes DelveInsight | Key Companies – UCB, Abbvie, Genetech, Gilead, Celgene, Millennium Pharma, and... 
Via Get News
Opinion: Building an Inclusive World Through Sports, Art, and Culture
SOURCE: Gilead Sciences 
Via 3BL Media
Topics LGBTQ
Exposures Diversity
Keto Benefits And Benefits of Drinking Ketones.
Via Marketers Media
Congratulations to Taiyin Yang, EVP, for Being Elected to the 2022 Class of the National Academy of Engineering.
SOURCE: Gilead Sciences 
Via 3BL Media
Mark Dresser Elected First Openly-LGBTQ+ President of American Society for Clinical Pharmacology and Therapeutics
SOURCE: Gilead Sciences 
Via 3BL Media
We're Proud to Have Supported a Special Issue of Tuskegee University's Journal of Healthcare, Science, and the Humanities
SOURCE: Gilead Sciences 
Via 3BL Media
Keto Vs Low Carb – Intermittent Fasting Vegan Diet For Weight Loss Site Relaunch
Via Marketers Media
Gilead Launches Pharmaceutical Education Program to Increase Workplace Diversity (Black Enterprise)
SOURCE: Gilead Sciences 
Via 3BL Media
Understanding Hepatitis D: 4 Questions With Professor Maria Buti
SOURCE: Gilead Sciences 
Via 3BL Media
Charting a Career to Help Reduce Health Inequity: Porscha's Story
SOURCE: Gilead Sciences 
Via 3BL Media
New Clinical Data Support the Sustained Efficacy of Long-acting Lenacapavir, Gilead’s Investigational HIV-1 Capsid Inhibitor
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences Invests in Research for COVID-19 Treatments for All Ages
SOURCE: Gilead Sciences 
Via 3BL Media
Exposures COVID-19
Phase 2/3 Interim Data Evaluating the Safety, Tolerability and Clinical Outcomes of Veklury® (Remdesivir) in Pediatric Patients With COVID-19 Presented at CROI 2022
From Gilead Sciences, Inc.
Via Business Wire
Biktarvy® Demonstrates High Efficacy and Durable Viral Suppression at Five Years, in Treatment-Naïve Adults
From Gilead Sciences, Inc.
Via Business Wire
Veklury® (Remdesivir) Retains Antiviral Activity Against Omicron, Delta and Other Emergent SARS-CoV-2 Variants in Multiple In Vitro Studies
From Gilead Sciences, Inc.
Via Business Wire
Ending HIV-Related Stigma in the Southern United States: Gina's Story
SOURCE: Gilead Sciences 
Via 3BL Media
What World Cancer Day Means to Me
SOURCE: Gilead Sciences 
Via 3BL Media
Gilead to Present Latest Antiviral Research and Development Data at CROI 2022 Addressing Urgent Global Needs
From Gilead Sciences, Inc.
Via Business Wire
Living Well With Hepatitis B: Lai's Journey
SOURCE: Gilead Sciences 
Via 3BL Media
Gilead Sciences Named a Best Place to Work for LGBTQ+ Equality in 2022
SOURCE: Gilead Sciences 
Via 3BL Media
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences Announces 2.8 Percent Increase in First Quarter 2022 Dividend
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences Announces Fourth Quarter and Full Year 2021 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
Inside the Innovation: Pharmaceutical Development and Manufacturing Leaders Share Experiences
SOURCE: Gilead Sciences 
Via 3BL Media
U.S. FDA Approves New Label Update for CAR T-Cell Therapy Yescarta® Showing Prophylactic Steriod Use Improves Management of Cytokine Release Syndrome
From Gilead Sciences, Inc.
Via Business Wire
HIV in the Time of COVID-19: The Case for Investment
SOURCE: Gilead Sciences 
Via 3BL Media
Exposures COVID-19
Improving HIV Care With Telehealth
SOURCE: Gilead Sciences 
Via 3BL Media
Exposures COVID-19
Gilead Announces Partial Clinical Hold for Studies Evaluating Magrolimab in Combination With Azacitidine
From Gilead Sciences Inc.
Via Business Wire
< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.